---
title: "Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy"
description: "Formulary evidence on Zeleciment rostudirsen (z-rostudirsen, DYNE-251) in Duchenne muscular dystrophy. Clinical evidence covers DELIVER, FORZETTO, PROMOVI, 22-ANGR-120, and TTE. 153 evidence topics quoted from 77 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Zeleciment rostudirsen

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Duchenne muscular dystrophy

<a id="topic-1.1.1-1"></a>

##### Summary

Duchenne muscular dystrophy is an X-linked dystrophinopathy associated with progressive weakness and respiratory, cardiac, and skeletal complications. A systematic review estimated birth prevalence at 19.8 per 100,000 live male births. A survival meta-analysis estimated median life expectancy at 28.1 years among those born after 1990. In a U.S. analysis with 782 matched pairs, mean annual healthcare costs were US$103,826.05 for the DMD cohort and US$3,225.30 for the non-muscular-dystrophy cohort. These estimates describe different populations and should not be combined into a product-specific economic estimate.

Source: [Duvuru et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1119/); [Crisafulli et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7275323/); [Broomfield et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8665435/); [Scavina et al. (2026)](https://link.springer.com/article/10.1007/s41669-025-00612-z)

<a id="heading-1.1.2"></a>

#### 1.1.2 Zeleciment rostudirsen Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

The DELIVER registrational expansion cohort included 32 participants, with 24 allocated to z-rostudirsen and 8 to placebo. At six months, mean absolute dystrophin was 5.46% of normal after muscle-content adjustment and 2.87% without adjustment. A post-hoc functional comparison used 21 treated participants and 18 pooled placebo participants. Reported differences were 0.04 rise/sec for TTR velocity and 0.2 m/sec for 10MWR velocity, both with nominal p<0.05; the NSAA difference was 2.1 points with nominal p=0.0894. No related serious TEAEs were reported in the registrational cohort. Related serious events occurred in extension participants, and higher-dose events included acute kidney injury, thrombocytopenia, and pancytopenia.

Source: [Dyne Therapeutics DELIVER topline results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12); [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf); [Dyne Therapeutics first quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-first-quarter-2026-financial-results); [Guglieri et al. (2025c)](https://www.dyne-tx.com/wp-content/uploads/Guglieri_2025_WMS_DELIVER%20Poster.pdf)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Zeleciment rostudirsen

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

FDA acceptance of the BLA and Priority Review do not establish approval. The reported target action date is January 21, 2027. The application uses dystrophin as a surrogate endpoint; the available functional comparisons remain exploratory. FORZETTO is the confirmatory Phase 3 trial. No product-specific budget impact model or acquisition price is available in the evidence reproduced here.

Source: [Dyne Therapeutics Biologics License Application acceptance announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-us-fda-acceptance-biologics-license); [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf); [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

## Related pages
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Product information and disease description](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Clinical evidence](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: References](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
